Showing 3861-3870 of 20452 results for "".
- Advancements in Brain Clearance Mechanisms: New Insights into Alzheimer's Diseasehttps://reachmd.com/news/advancements-in-brain-clearance-mechanisms-new-insights-into-alzheimers-disease/2484527/Researchers from Nanyang Technological University report that enlarged perivascular spaces visible on routine MRI are a significant early marker of Alzheimer's disease. Detecti
- Mechanistic Insights into Tirzepatide’s Transient Influence on Food Cravingshttps://reachmd.com/news/mechanistic-insights-into-tirzepatides-transient-influence-on-food-cravings/2484505/In a case study from the University of Pennsylvania Perelman School of Medicine, tirzepatide produced short-liv
- FDA Approval and Clinical Integration of Tryptyr for Dry Eye Diseasehttps://reachmd.com/news/fda-approval-and-clinical-integration-of-tryptyr-for-dry-eye-disease/2484508/The FDA approved Tryptyr, a first-in-clas
- Agomab's Ontunisertib in Fibrostenosing Crohn's Disease: Phase 2a Results and Future Implicationshttps://reachmd.com/news/agomabs-ontunisertib-in-fibrostenosing-crohns-disease-phase-2a-results-and-future-implications/2484485/Agomab reports positive Phase 2a topline data for ontunisertib in fibros
- Breakthrough in Liver Cancer Detection: The ALTUS Trial's Implications for Clinical Practicehttps://reachmd.com/news/breakthrough-in-liver-cancer-detection-the-altus-trials-implications-for-clinical-practice/2484491/The ALTUS trial
- Innovations in Retinal Gene Therapy: Insights from the BIRD-1 Trialhttps://reachmd.com/news/innovations-in-retinal-gene-therapy-insights-from-the-bird-1-trial/2484488/Opus Genetics has dosed the first patient in the
- Advancing Internal Dosimetry in Personalized Nuclear Medicine: Toward Optimized Radiopharmaceutical Usehttps://reachmd.com/news/advancing-internal-dosimetry-in-personalized-nuclear-medicine-toward-optimized-radiopharmaceutical-use/2484487/MCNP6, GATE and GAMOS now produce convergent organ-absorbed dose estimates, reducing cross-platform variability and enabling actionable, patient-specific radiopharmaceu
- Cemiplimab Monotherapy in Metastatic NSCLC: Insights from the CEMI-SPA National Spanish Cohorthttps://reachmd.com/news/cemiplimab-monotherapy-in-metastatic-nsclc-insights-from-the-cemi-spa-national-spanish-cohort/2484452/In 150 patients with metastatic NSCLC and PD‑L1 ≥50%, the CEMI‑SPA national Spanish cohort clarifies real‑world effectiveness and safety of first‑line
- Innovations in Lung Cancer Care: Single-Anesthesia Bronchoscopy and Resectionhttps://reachmd.com/news/innovations-in-lung-cancer-care-single-anesthesia-bronchoscopy-and-resection/2484448/Riverside Health System's Single-Anesthesia Bronchoscopy and Resection (SABR) st
- Efficacy and Safety of Evolocumab in Primary Prevention: Insights from Recent Trialshttps://reachmd.com/news/efficacy-and-safety-of-evolocumab-in-primary-prevention-insights-from-recent-trials/2484434/In a pivotal trial, evolocumab reduced the risk of a first major cardiovascular event by 25% (three‑point